Skip to main content

Table 3 Adverse reactions to DAAs in the study groups

From: Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease

 

Patients with cryoglobulinemia

(N = 56)

Patients with SLE (N = 5)

Patients with CKD (hypertensive or diabetic) (N = 111)

Patients undergoing hemodialysis (N = 48)

Patients after kidney transplantation (N = 12)

Asthenia/ Fatigue

10 pts. (17.8%)

2pts (40%)

50 pts. (45%)

7 pts. (14.5%)

2 pts. (16.6%)

Nausea

8 pts. (14.2%)

0 pts

22 pts. (20%)

12 pts. (25%)

3 pts. (25%)

Headache

17pts (30.3%)

2 pts. (20%)

36 pts. (33%)

8 pts. (16,6%)

0 pts

Diarrhea

2 pts. (3.5%)

0 pts

7 pts. (6.3%)

3 pts. (6.2%)

1 pts. (8.3%)

Dizziness

12 pts. (21.4%)

1 pts. (20%)

41 pts. (36.9%)

10 pts. (20.8%)

1 pts. (8.3%)